Prodrugs--from serendipity to rational design.

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.
Pharmacological reviews (Impact Factor: 17). 09/2011; 63(3):750-71. DOI: 10.1124/pr.110.003459
Source: PubMed

ABSTRACT The prodrug concept has been used to improve undesirable properties of drugs since the late 19th century, although it was only at the end of the 1950s that the actual term prodrug was introduced for the first time. Prodrugs are inactive, bioreversible derivatives of active drug molecules that must undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then elicit its desired pharmacological effect in the body. In most cases, prodrugs are simple chemical derivatives that are only one or two chemical or enzymatic steps away from the active parent drug. However, some prodrugs lack an obvious carrier or promoiety but instead result from a molecular modification of the prodrug itself, which generates a new active compound. Numerous prodrugs designed to overcome formulation, delivery, and toxicity barriers to drug utilization have reached the market. In fact, approximately 20% of all small molecular drugs approved during the period 2000 to 2008 were prodrugs. Although the development of a prodrug can be very challenging, the prodrug approach represents a feasible way to improve the erratic properties of investigational drugs or drugs already on the market. This review introduces in depth the rationale behind the use of the prodrug approach from past to present, and also considers the possible problems that can arise from inadequate activation of prodrugs.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: As part of a larger study synthesizing a more directed form of chemotherapy, we have begun to assess the efficacy of different potential toxins that could be delivered locally rather than systemically. In doing so, we hope to reduce the systemic side effects commonly observed, while maintaining a high level of toxicity and eliminating the need for metabolic alterations. In a search for this more efficient method for killing cancerous cells, we have begun studying cantharidin, a toxin used in traditional Chinese medicine, as a potential chemotherapeutic. Using an MTT cell viability assay, the toxicity of cantharidin was compared to both cyclophosphamide and paclitaxel in three different breast cancer cell lines: MCF-7, MDA-MB-231, and SK-BR-3. Increasing the concentration of chemotherapy drugs did decrease cell viability in all cell lines when cantharidin and cyclophosphamide were applied; however differences for paclitaxel were cell-specific. Additionally, cantharidin exhibited the highest decrease in cell viability regardless of cell type, indicating it may be a much more potent and less specific chemotherapeutic. These results will help us move forward in developing a potentially more potent treatment for breast cancer that might eliminate the need for subtype-specific treatments.
    International journal of breast cancer. 01/2014; 2014:423059.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present work deals with the synthesis of diester-dicarboxylic acid (DEDA)-Melamine co-crystal, characterized using UV-Visible absorption, scanning electron microscope and X-ray diffraction techniques. Single crystal X-ray analysis is carried out to confirm the formation of DEDA-Melamine co-crystal. Phthalic anhydride is used as the main source for synthesising the diesterdicarboxylic acid. By desymmetrizing phthalic anhydride, diester-dicarboxylic acid is synthesised. The synthesised diesterdicarboxylic acids are used for the reaction with melamine to obtain diesterdicarboxylic acid-Melamine co-crystal. The host-guest chemistry of diesterdicarboxylic acid, Melamine and their DEDA-Melamine co-crystal with β-cyclodextrin is also explored. Cocrystallization with pharmaceutically acceptable compounds does not affect pharmacological activity of API, but can improve physical properties, Such as aqueous solubility, hygroscopicity etc., [7-9]. Hydrogen bonds are the basis of molecular recognition phenomena in pharmaceutical systems and are responsible for the generation of families of molecular networks with the same molecular components (single component crystals and their polymorphs) or with different molecular components (multiple component crystals or cocrystal) in the crystalline state [10]. Knowledge of the intermolecular interactions and their effects on crystal packing allowed for the engineering of co-crystals with desired physical and chemical properties. Complexes resulting from entrapment of one compound in the molecular framework of other are considered as complexes of occlusion or inclusion complexes [11]. Directing a drug to
    01/2014; 1(1):104.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Palladium-activated prodrug therapy is an experimental therapeutic approach that relies on the unique chemical properties and biocompatibility of heterogeneous palladium catalysis to enable the spatially-controlled in vivo conversion of a biochemically-stable prodrug into its active form. This strategy, which would allow inducing local activation of systemically administered drug precursors by mediation of an implantable activating device made of Pd(0), has been proposed by our group as a way to reach therapeutic levels of the active drug in the affected tissue/organ while reducing its systemic toxicity. In the seminal study of such an approach, we reported that propargylation of the N1 position of 5-fluorouracil suppressed the drug's cytotoxic properties, showed high stability in cell culture and facilitated the bioorthogonal restoration of the drug's pharmacological activity in the presence of extracellular Pd(0)-functionalized resins. To provide additional insight on the properties of this system, we have investigated different N1-alkynyl derivatives of 5-fluorouracil and shown that the presence of substituents near the triple bond influence negatively on its sensitivity to palladium catalysis under biocompatible conditions. Comparative studies of the N1- vs. the N3-propargyl derivatives of 5-fluorouracil revealed that masking each or both positions equally led to inactive derivatives (>200-fold reduction of cytotoxicity relative to the unmodified drug), whereas the depropargylation process occurred faster at the N1 position than at the N3, thus resulting in greater toxigenic properties in cancer cell culture.
    Frontiers in chemistry. 01/2014; 2:56.


Available from
May 21, 2014